The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,262.00
Bid: 12,262.00
Ask: 12,266.00
Change: -142.00 (-1.14%)
Spread: 4.00 (0.033%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Recharged hopes of Brexit deal, trade truce power UK shares

Thu, 10th Oct 2019 09:40

* FTSE 100, FTSE 250 up 0.3%

* Mondi reverses course to close higher

* Miners biggest boost to main index

* FTSE 100 confirms "Death Cross" pattern
(Adds company news items, updates share moves, changes analyst
comments)

By Muvija M and Shashwat Awasthi

Oct 10 (Reuters) - London stocks finished a roller coaster
session on Thursday with gains as domestic companies rose after
Britain and Ireland said they saw a pathway to a Brexit deal,
and international names jumped on to a global rally over hopes
of a U.S.-China trade truce.

The FTSE 100 ended 0.3% higher, after flipping back
and forth during the day on mixed signals over the state of
affairs between Beijing and Washington, while the midcap index
that has a greater UK exposure also rose by the same level.

However, a more than 1% surge in sterling on renewed
prospects of a Brexit agreement kept a lid on gains for the
blue-chip bourse, which earns a sizeable portion of its earnings
in the U.S. dollar.

Spirits company Diageo, consumer goods giant
Unilever and AstraZeneca were among stocks
hammered the most, causing the FTSE 100 to lag other major
indexes.

Stocks vulnerable to a hit from Brexit, on the other hand,
overpowered those losses. Lloyds topped the main board
with a 4% leap, while Royal Bank of Scotland added 3%.

Mining heavyweights, which rely on world's top metals
consumer China for a chunk of their profits, were the biggest
sector-wise boost to the main bourse, climbing 2.5% - their most
since early August.

Gains were triggered as hopes of a resolution to a painfully
long trade war returned after U.S. President Donald Trump said
he will meet Chinese Vice Premier Liu He on Friday.

The comments were well received, given they came after
sentiment had turned sour following a report that Beijing has
urged Washington to stop unreasonable pressure on Chinese
companies.

On news-related moves, FTSE 100 component Mondi
reversed earlier losses to close 2% higher after a third-quarter
update, while homewares retailer Dunelm slumped 10% to
the bottom of the midcap index after it flagged a softer market.

Still, reflecting recent worries over trade and Brexit, the
FTSE 100 confirmed a "Death Cross" pattern as its 50-day moving
average (DMA) crossed below the 200 DMA, which is seen a warning
sign that more losses are likely in the near term.

The blue-chip bourse last formed the pattern roughly a year
ago when Brexit negotiations and Italy's budget deficit had hit
risk appetite.

"The ebb and flow of sentiment around U.S., China trade
continues to pull global stock markets from pillar to post," CMC
Markets' Michael Hewson wrote.

(Reporting by Muvija M and Shashwat Awasthi in Bengaluru;
Editing by Bernard Orr and Giles Elgood)

More News
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.